History Timeline

2016

NEW WEBSITE LAUNCH !

2014

Small scale manufacturing and R&D begins in the DRG Headquarters in USA, managed by several additional staff

2013

Introduction for distribution of the DRG:HYBRiD-XLTM continues through international approval processes with great success Continued development of Elisa kits to utilize with DRG:HYBRiD-XLTM Expanded growth in several international markets including China

2012

New US Headquarters established in Springfield, New Jersey with expanded laboratory space and distribution DRG:HYBRiD-XLTM continues through international approval processes with great success

2011

Introduction of CA 72-4 (FDA Registration now underway)

2010

United States Patent Office issues two more patents to DRG International for development of Hepcidin diagnostic kits DRG International unveils the DRG: HYBRiD-XL® fully-automatic, random access analyzer for immunoassays and clinical chemistry to revolutionize laboratory procedures!

2009

Introduction to market of DRG® Renin, PLGF, Afamin, Anti-Amyloid, Cripto-1, CYR61, L1-Cam, and NOV Elisa kits

2008

United States Patent Office issues two patents to DRG International for development of Hepcidindiagnostic kits

2004

DRG® develops Tumor Markers, CA 72-4, CA 125, CA 15-3, CA 19-9, Cyfra21-1 and introduces Corticosterone andEstrone ELISAs

2003

DRG® develops and introduces the first worldwide Assay for the measurement of Hepcidin DRG® acquires Novum-Diagnostics in Dietzenbach and takes over production of more than 70 ELISAs for Infectious diseases in the DRG-Novum Branch Lab

2002

DRG® develops and introduces various Saliva -and DHEA –ELISAs

2000

DRG® develops and Introduces IGF1, IL-6,Cortisol- Saliva, Androstenedione ELISAs DRG® received certification for QM-System EN ISO9001:1994 DNVon October 27th Dade BehringTechnology is transferred to DRG® production of C5a and PAP – ELISAs

1999

DRG® develops and introduces Insulin, PAPP-A, and TGFßII ELISAs

1998

DRG® moves to a new building in Marburg, Germany DRG Instruments GmbH celebrates 25 years in Marburg, Germany

1997

DRG® develops and introduces Leptin, TGFß,and ß-HCG ELISAs

1996

DRG® develops and introduces Free Estriol ELISA

1995

DRG® develops and Introduces the first worldwide, non-radioactive C-Peptide and Proinsulin Assays

1994

DRG® develops and introduces DHEA-S, Progesterone, Testosterone, PMSG, and βGH ELISAs DRG® opens DRG Diagnostics Branch Office in Berlin, Germany

1993

DRG Techsystemsis founded in Moscow, Russa DRG® develops and introduces 17-OH-Progesterone ELISA

1992

DRG Sp.O.O. is founded in Brno, Czechoslovakia (Czech Rep.) DRG® develops and introduces AFP, HCG, FSH, Prolactin and LH

1991

DRG Biomed founded in St. Petersburg, Russia DRG® launches first neonatal entry of DRG®-ELISA:HPL

1990

DRG MEDTEK founded in Warsaw, Poland DRG® begins R&D and ELISA production in Marburg, Germany

1988

DRG AG founded in Zürich,Switzerland

1985

DRG® begins in-house R&D Operations

1982

DRG® expands in Eastern and Western Europe

1981

DRG® introduces the Mechanical Heart Valve on European Cardiac Surgery Market

1974

DRG Instruments GmbH moves to Marburg, Germany

1973

Distribution of RIA`s in Germany begins DRG Instruments GmbH is founded in Munich, Germany

1970

DRG International, Inc. Is founded by Dr. C.E. Geacintov in New Jersey, USA DRG® enters market in Europe, USSR, Poland and Yugoslavia.

Sign Up for Our Newsletter

  • By submitting this form, you are granting: DRG International, Inc., 841 Mountain Avenue, Springfield, NJ, 07081, permission to email you. You may unsubscribe via the link found at the bottom of every email. (See our Email Privacy Policy (http://constantcontact.com/legal/privacy-statement) for details.) Emails are serviced by Constant Contact.